Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 2/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15265284 | 0.79 | BIRC2 (0.45) | MMP3MEN1KMT2A | |
| SCHEMBL15413165 | 0.79 | BIRC2 (0.45) | MMP3MEN1KMT2A | |
| SCHEMBL28552378 | 0.79 | ZDHHC7 (0.58) | GPR84FFAR1ZDHHC7FAAHABCB1 | |
| SCHEMBL29205062 | 0.78 | GPR84 (0.42) | GPR84FFAR1FAAH | |
| SCHEMBL29205060 | 0.78 | GPR84 (0.42) | GPR84FFAR1FAAH | |
| SCHEMBL27200569 | 0.78 | GPR84 (0.43) | MMP3GPR84FFAR1FAAHFFAR4 | |
| SCHEMBL2374655 | 0.78 | GPR84 (0.43) | MMP3GPR84FFAR1FAAHFFAR4 | |
| SCHEMBL29205061 | 0.78 | GPR84 (0.42) | GPR84FFAR1FAAH | |
| SCHEMBL14915950 | 0.78 | GPR84 (0.43) | MMP3GPR84FFAR1FAAHFFAR4 | |
| SCHEMBL28037989 | 0.78 | ZDHHC7 (0.41) | GPR84FFAR1ZDHHC7FAAHMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11185544-B2 | Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-l,2-dithiole-3-thione, taste-modified formulations, and methods of making and using same | ST IP HOLDING AG (CH) | 2021-11-30 | — | — | US | disclosed |
| US-20190209557-A1 | Formulations of 4-Methyl-5-(Pyrazin-2-yl)-3H-1,2-Dithiole-3-Thione, Taste-Modified Formulations, and Methods of Making and Using Same | ZPNE GROUP GMBH (CH) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209557-A1 | Formulations of 4-Methyl-5-(Pyrazin-2-yl)-3H-1,2-Dithiole-3-Thione, Taste-Modified Formulations, and Methods of Making and Using Same | TAS2R5, TAS2R3, TAS2R16 | MMP3 4415/4885GPR84 2524/4885FFAR1 1428/4885 |
| US-11185544-B2 | Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-l,2-dithiole-3-thione, taste-modified formulations, and methods of making and using same | TAS2R5, TAS2R3, TAS2R16 | MMP3 4405/4885GPR84 2695/4885FFAR1 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.